These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17102701)

  • 1. Neuropharmacological modulation of cognition.
    Chamberlain SR; Müller U; Robbins TW; Sahakian BJ
    Curr Opin Neurol; 2006 Dec; 19(6):607-12. PubMed ID: 17102701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
    Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacology of human working memory.
    Ellis KA; Nathan PJ
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):299-313. PubMed ID: 11602036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuropharmacology of impulsive behaviour.
    Pattij T; Vanderschuren LJ
    Trends Pharmacol Sci; 2008 Apr; 29(4):192-9. PubMed ID: 18304658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of attention deficits in neurological disorders.
    Coulthard E; Singh-Curry V; Husain M
    Curr Opin Neurol; 2006 Dec; 19(6):613-8. PubMed ID: 17102702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration.
    Elsworth JD; Groman SM; Jentsch JD; Valles R; Shahid M; Wong E; Marston H; Roth RH
    Neuropharmacology; 2012 Mar; 62(3):1442-52. PubMed ID: 21875607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noradrenergic modulation of cognition: therapeutic implications.
    Chamberlain SR; Robbins TW
    J Psychopharmacol; 2013 Aug; 27(8):694-718. PubMed ID: 23518815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
    Cools R; Stefanova E; Barker RA; Robbins TW; Owen AM
    Brain; 2002 Mar; 125(Pt 3):584-94. PubMed ID: 11872615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific abnormalities in serotonin release in the prefrontal cortex of isolation-reared rats measured during behavioural performance of a task assessing visuospatial attention and impulsivity.
    Dalley JW; Theobald DE; Pereira EA; Li PM; Robbins TW
    Psychopharmacology (Berl); 2002 Nov; 164(3):329-40. PubMed ID: 12424557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral Experimental Paradigms for the Evaluation of Drug's Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory.
    Zameer S; Akhtar M; Vohora D
    CNS Neurol Disord Drug Targets; 2019; 18(3):185-204. PubMed ID: 30648527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognition: the ultimate brain function.
    Robbins TW
    Neuropsychopharmacology; 2011 Jan; 36(1):1-2. PubMed ID: 21116247
    [No Abstract]   [Full Text] [Related]  

  • 12. The neuropsychiatry of impulsivity.
    Chamberlain SR; Sahakian BJ
    Curr Opin Psychiatry; 2007 May; 20(3):255-61. PubMed ID: 17415079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention.
    Callahan PM; Terry AV
    Handb Exp Pharmacol; 2015; 228():161-89. PubMed ID: 25977082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive deficits in major depression and a new theory of ADHD: a model of impaired antagonism of cholinergic-mediated prepotent behaviours in monoamine depleted individuals.
    Vakalopoulos C
    Med Hypotheses; 2007; 68(1):210-21. PubMed ID: 16997497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impulsivity in adult ADHD patients with and without cocaine dependence.
    Crunelle CL; Veltman DJ; van Emmerik-van Oortmerssen K; Booij J; van den Brink W
    Drug Alcohol Depend; 2013 Apr; 129(1-2):18-24. PubMed ID: 23026814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulsivity, attention, memory, and decision-making among adolescent marijuana users.
    Dougherty DM; Mathias CW; Dawes MA; Furr RM; Charles NE; Liguori A; Shannon EE; Acheson A
    Psychopharmacology (Berl); 2013 Mar; 226(2):307-19. PubMed ID: 23138434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficits in bipolar disorders: Implications for emotion.
    Lima IMM; Peckham AD; Johnson SL
    Clin Psychol Rev; 2018 Feb; 59():126-136. PubMed ID: 29195773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses.
    Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140
    [No Abstract]   [Full Text] [Related]  

  • 19. COMT as a drug target for cognitive functions and dysfunctions.
    Scheggia D; Sannino S; Scattoni ML; Papaleo F
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):209-21. PubMed ID: 22483296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery.
    Chamberlain SR; Robbins TW; Winder-Rhodes S; Müller U; Sahakian BJ; Blackwell AD; Barnett JH
    Biol Psychiatry; 2011 Jun; 69(12):1192-203. PubMed ID: 21047621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.